According to Transpire Insight, the Global Liquid Biopsy Market size was valued at USD 8.73 Billion in 2025 and is projected to reach USD 26.30 Billion by 2033, expanding at a rapid CAGR of 14.78% from 2026 to 2033. Driven by breakthroughs in non-invasive biomarker detection, Next-Generation Sequencing (NGS), and multi-analyte assays, liquid biopsies are transforming oncology care through early cancer screening, therapy selection, and real-time disease monitoring.

Market Size & Forecast

The Global Liquid Biopsy Market was valued at USD 8.73 Billion in 2025 and is expected to reach USD 26.30 Billion by 2033. Between 2026 and 2033, the market is set to register a high compound annual growth rate (CAGR) of 14.78%. Expansion is fueled by the growing clinical shift away from invasive tissue biopsies toward minimally invasive blood, plasma, and urine testing, supported by favorable reimbursement policies and expanded FDA approvals.

Key Market Trends & Insights

• Circulating Tumor DNA (ctDNA) Lead: ctDNA-based testing holds a prominent position in the market due to its precision in identifying actionable genetic mutations, minimal residual disease (MRD), and targeted treatment resistance profiles.
• Rise of Multi-Analyte & Methylation Assays: Multi-analyte tests and epigenetic methylation profiling represent the fastest-growing technology segments, enabling multi-cancer early detection (MCED) from a single blood draw.
• Cancer Screening & Therapy Selection: While disease monitoring and companion diagnostics dominate current clinical volume, population-wide early cancer detection programs are emerging as major long-term revenue drivers.
• Cell-Free RNA & Exosomes: Emerging biomarker platforms incorporating circulating tumor cells (CTCs), extracellular vesicles, and microRNA are expanding clinical utility beyond oncology into pre-natal and organ transplant monitoring.

Regional Insights

• North America: Commands the largest share of the global liquid biopsy market, supported by major diagnostic infrastructure, extensive clinical trial activity, rapid commercial adoption of NGS platforms, and progressive Medicare coverage for MRD testing.
• Europe: Maintains a strong market footprint, driven by government-backed genomic initiatives, academic clinical validation networks, and expanding access to targeted cancer therapies.
• Asia Pacific: Projected to experience rapid growth, fueled by rising cancer incidence, expanding healthcare expenditure, increasing clinical trial footprints, and localized development of affordable diagnostic assays in China, Japan, and India.

Major Key Players

• Guardant Health, Inc.
• Foundation Medicine, Inc. (Roche)
• GRAIL, Inc. (Illumina)
• Exact Sciences Corporation
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Natera, Inc.
• Myriad Genetics, Inc.
• NeoGenomics Laboratories

Outlook

• Integration of Artificial Intelligence: Machine learning algorithms will play an increasingly central role in signal extraction and computational genomic analysis for ultra-low concentration biomarker identification.
• Expansion of Multi-Cancer Early Detection (MCED): Large-scale prospective clinical trials will support broader regulatory approvals and routine asymptomatic population screening.
• Clinical Workflow Standardisation: Industry partnerships will streamline sample preservation, automated extraction, and bioinformatics pipelines to standardize global liquid biopsy diagnostics across clinical networks.

Top Reports:

https://www.transpireinsight.com/he/report/north-america-high-speed-camera-market

https://www.transpireinsight.com/fr/report/europe-ai-eda-market

https://www.transpireinsight.com/ru/report/europe-ai-eda-market

https://www.transpireinsight.com/ko/report/europe-aerospace-bearings-market

https://www.transpireinsight.com/ar/report/europe-aerospace-bearings-market